Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

158 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Systemic Barriers to Risk-Reducing Interventions for Hereditary Cancer Syndromes: Implications for Health Care Inequities.
Mittendorf KF, Knerr S, Kauffman TL, Lindberg NM, Anderson KP, Feigelson HS, Gilmore MJ, Hunter JE, Joseph G, Kraft SA, Zepp JM, Syngal S, Wilfond BS, Goddard KAB. Mittendorf KF, et al. Among authors: goddard kab. JCO Precis Oncol. 2021 Nov 3;5:PO.21.00233. doi: 10.1200/PO.21.00233. eCollection 2021. JCO Precis Oncol. 2021. PMID: 34778694 Free PMC article. Review. No abstract available.
Participant Reactions to a Literacy-Focused, Web-Based Informed Consent Approach for a Genomic Implementation Study.
Kraft SA, Porter KM, Duenas DM, Guerra C, Joseph G, Lee SS, Shipman KJ, Allen J, Eubanks D, Kauffman TL, Lindberg NM, Anderson K, Zepp JM, Gilmore MJ, Mittendorf KF, Shuster E, Muessig KR, Arnold B, Goddard KAB, Wilfond BS. Kraft SA, et al. Among authors: goddard kab. AJOB Empir Bioeth. 2021 Jan-Mar;12(1):1-11. doi: 10.1080/23294515.2020.1823907. Epub 2020 Sep 26. AJOB Empir Bioeth. 2021. PMID: 32981477 Free PMC article.
Adaptation and early implementation of the PREdiction model for gene mutations (PREMM5™) for lynch syndrome risk assessment in a diverse population.
Mittendorf KF, Ukaegbu C, Gilmore MJ, Lindberg NM, Kauffman TL, Eubanks DJ, Shuster E, Allen J, McMullen C, Feigelson HS, Anderson KP, Leo MC, Hunter JE, Sasaki SO, Zepp JM, Syngal S, Wilfond BS, Goddard KAB. Mittendorf KF, et al. Among authors: goddard kab. Fam Cancer. 2022 Apr;21(2):167-180. doi: 10.1007/s10689-021-00243-3. Epub 2021 Mar 23. Fam Cancer. 2022. PMID: 33754278 Free PMC article.
Cancer Health Assessments Reaching Many (CHARM): A clinical trial assessing a multimodal cancer genetics services delivery program and its impact on diverse populations.
Mittendorf KF, Kauffman TL, Amendola LM, Anderson KP, Biesecker BB, Dorschner MO, Duenas DM, Eubanks DJ, Feigelson HS, Gilmore MJ, Hunter JE, Joseph G, Kraft SA, Lee SSJ, Leo MC, Liles EG, Lindberg NM, Muessig KR, Okuyama S, Porter KM, Riddle LS, Rolf BA, Rope AF, Zepp JM, Jarvik GP, Wilfond BS, Goddard KAB; CHARM study team. Mittendorf KF, et al. Among authors: goddard kab. Contemp Clin Trials. 2021 Jul;106:106432. doi: 10.1016/j.cct.2021.106432. Epub 2021 May 11. Contemp Clin Trials. 2021. PMID: 33984519 Free PMC article. Clinical Trial.
Impact of expanded carrier screening on health care utilization.
Kauffman TL, Dickerson JF, Lynch FL, Leo MC, Shuster E, Wilfond BS, Himes P, Gilmore MJ, Rollins NJ, Goddard KAB. Kauffman TL, et al. Among authors: goddard kab. Am J Manag Care. 2021 Aug;27(8):316-321. doi: 10.37765/ajmc.2021.88722. Am J Manag Care. 2021. PMID: 34460173 Free article. Clinical Trial.
Motivations and concerns of patients considering participation in an implementation study of a hereditary cancer risk assessment program in diverse primary care settings.
Duenas DM, Shipman KJ, Porter KM, Shuster E, Guerra C, Reyes A, Kauffman TL, Hunter JE, Goddard KAB, Wilfond BS, Kraft SA. Duenas DM, et al. Among authors: goddard kab. Genet Med. 2022 Mar;24(3):610-621. doi: 10.1016/j.gim.2021.11.017. Epub 2021 Nov 23. Genet Med. 2022. PMID: 34906471 Free PMC article.
Corrigendum to "Cancer Health Assessments Reaching Many (CHARM): A clinical trial assessing a multimodal cancer genetics services delivery program and its impact on diverse populations" [Contemporary Clinical Trials 106 (2021) 106432].
Mittendorf KF, Kauffman TL, Amendola LM, Anderson KP, Biesecker BB, Dorschner MO, Duenas DM, Eubanks DJ, Feigelson HS, Gilmore MJ, Hunter JE, Joseph G, Kraft SA, Lee SSJ, Leo MC, Liles EG, Lindberg NM, Muessig KR, Okuyama S, Porter KM, Riddle LS, Rolf BA, Rope AF, Zepp JM, Jarvik GP, Wilfond BS, Goddard KAB; CHARM study team. Mittendorf KF, et al. Among authors: goddard kab. Contemp Clin Trials. 2022 Mar;114:106682. doi: 10.1016/j.cct.2022.106682. Epub 2022 Feb 3. Contemp Clin Trials. 2022. PMID: 35123916 Free article. No abstract available.
Retrospective assessment of barriers and access to genetic services for hereditary cancer syndromes in an integrated health care delivery system.
Muessig KR, Zepp JM, Keast E, Shuster EE, Reyes AA, Arnold B, Ingphakorn C, Gilmore MJ, Kauffman TL, Hunter JE, Knerr S, Feigelson HS, Goddard KAB. Muessig KR, et al. Among authors: goddard kab. Hered Cancer Clin Pract. 2022 Feb 10;20(1):7. doi: 10.1186/s13053-022-00213-5. Hered Cancer Clin Pract. 2022. PMID: 35144679 Free PMC article.
Laboratory-related outcomes from integrating an accessible delivery model for hereditary cancer risk assessment and genetic testing in populations with barriers to access.
Amendola LM, Shuster E, Leo MC, Dorschner MO, Rolf BA, Shirts BH, Gilmore MJ, Okuyama S, Zepp JM, Kauffman TL, Mittendorf KF, Bellcross C, Jenkins CL, Joseph G, Riddle L, Syngal S, Ukaegbu C, Goddard KAB, Wilfond BS, Jarvik GP; CHARM Study. Amendola LM, et al. Among authors: goddard kab. Genet Med. 2022 Jun;24(6):1196-1205. doi: 10.1016/j.gim.2022.02.006. Epub 2022 Mar 16. Genet Med. 2022. PMID: 35305866 Free article.
158 results